Oncology
AstraZeneca has been developing cancer medicines for more than 40 years. Many of these have increased survival rates for patients in the UK and around the world. Even as R&D continues to push boundaries in how we understand and fight cancer, there is still more to do.
We are at the heart of oncology R&D in the UK and are committed to advancing the science of oncology to deliver life-changing medicines. Our ambition is to eliminate cancer as a cause of death through scientific discovery and collaborations and ensure that these reach people in most need.
- IMFINZI▼(durvalumab) - Great Britain Prescribing Information
- IMFINZI▼(durvalumab) - Northern Ireland Prescribing Information
- Faslodex (fulvestrant) Prescribing Information
- Iressa (gefitinib) - Great Britain Prescribing Information
- Iressa (gefitinib) - Northern Ireland Prescribing Information
- Lynparza (olaparib) - (tablets) ovarian cancer - Great Britain Prescribing information
- Lynparza (olaparib) - (tablets) ovarian cancer - Northern Ireland Prescribing information
- Lynparza (olaparib) - (tablets) prostate cancer - Great Britain Prescribing information
- Lynparza (olaparib) - (tablets) prostate cancer - Northern Ireland Prescribing information
- Tagrisso▼ (osimertinib) - Great Britain Prescribing Information
- Tagrisso▼ (osimertinib) - Northern Ireland Prescribing Information
- Zoladex (goserelin) Prescribing Information
GB-37921 July 2022